David Schlosser

Spurge Technologies owns and operates a proprietary trading desk and CryptoStrada, a cryptocurrency brokerage firm.

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.

At Anglr, we live for the water. Powered by a network of passionate fishermen, it is our mission to better sport fishing through a dedication to discovery, friendship, fishing and memories. Fishing is best when we can enjoy it with friends, catch target species and relive adventures on the water. Anglr’s platform makes it possible to connect, improve and relive every fishing memory. Anglr’s fishing technology elevates your trips through one-of-a-kind features designed to compliment each step of the fishing journey. Whether you’re planning a weekend or simply looking for boat ramp access, recording a trip or logging a catch, determined to improve or wanting to relive your favorite memories on the water, our platform makes it possible. Our solutions are designed to evolve the way anglers plan trips, track fishing behaviors, tell stories, compete, and catch fish on the next wave of convergent disruption. www.ANGLR.com

Spurge Technologies owns and operates a proprietary trading desk and CryptoStrada, a cryptocurrency brokerage firm.

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.